Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 4, 1996, Pages 307-310

  Charalambous, D ^a   O'Brien, P E ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

colon cancer; prostaglandin; rat; sulindac

Indexed keywords

DRUG METABOLITE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON CANCER; CONTROLLED STUDY; CRYPT CELL; DRUG EFFECT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; TUMOR GROWTH;

EID: 0029974533     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb01376.x     Document Type: Article

References (25)

1. 1 Hucker HB, Stauffer SC, White SD et al. Physiological disposition and metabolic fate of a new anti‐inflammatory agent, cis ‐5‐fluoro‐2–methyl‐1–[ p ‐(methylsulfinyl)‐benzylidenyl]‐indene‐3–acetic acid in the rat, dog, rhesus monkey and man. Drug Metab. Disp. 1973 ; 1: 721–36.
2. 2 Van Arman CG, Risley EA, Nuss GW, Hucker HB, Duggan DE. Pharmacology of sulindac. In: Huskisson EC, Franchimont P., eds. CLINORIL in the Treatment of Rheumatic Disorders. New York: Raven Press, 1976 ; 9–36.
3. 3 Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumours in the rat. Arch. Surg. 1991 ; 126: 1094–6.
4. 4 Charalambous D., Farmer KC, O'Brien PE. Dose dependent effect of sulindac on experimental colon tumours in the rat. J. Gastroenterol. Hepatol. 1993 ; 8: A6.
5. 5 Charalambous D., Farmer C., O'Brien PE. Sulindac inhibits formation of aberrant crypt foci in dimethylhy‐drazine treated rats. J. Gastroenterol. Hepatol. 1994 ; 9: A73.
6. 6 Labayle D., Fischer D., Vielh P. et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991 ; 101: 635–9.
7. 7 Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993 ; 328: 1313–16.
8. 8 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin‐like drugs. Nature N. Biol. 1971 ; 231: 232–5.
9. 9 Hubbard WC, Alley MC, McLemore TL, Boyd MR. Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate and ovarian tumours. Cancer Res. 1988 ; 48: 4770–5.
10. 10 Rigas B., Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993 ; 122: 518–23.
11. 11 Metzger U., Meier J., Uhlschmid G., Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH‐induced rat colon cancer. Dis. Colon Rectum 1984 ; 27: 366–9.
12. 12 Pepin P., Bouchard L., Nicole P., Castonguay A. Effects of sulindac and oltipraz on the tumourigenicity of 4‐(methylnitrosamino)1‐(3–pyridyl)‐1‐butanone in A/J mouse lung. Carcinogenesis 1992 ; 13: 341–8.
13. 13 Hixson LJ, Alberts DS, Krutzsch M. et al. Antiproliferative effect of nonsteroidal anti‐inflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomarkers Prev. 1994 ; 3: 433–8.
14. 14 Shen TY. Indomethacin sulindac and their analogues. In: Rainsford KD, ed. Anti‐Inflammatory and Anti‐Rheumatic Drugs, vol. 1. Boca Raton (FL): CRC Press, 1985 ; 149–59.
15. 15 Duggan DE, Hooke KF, Noll RM, Hucker HB, Van Arman G. Comparative disposition of sulindac and metabolites in five species. Biochem. Pharmacol. 1978 ; 27: 2311–20.
16. 16 Jacobson M., Sharma YR, Cotlier E., Hollander JD. Diabetic complications in lens and nerve and their prevention by sulindac and sorbinil: Two novel aldose reductase inhibitors. Invest. Ophthalmol. Vis. Sci. 1983 ; 1426–9.
17. 17 Thomas DM, Mahendroo PP, Lou MF. Dynamic phosphorus 31 NMR study of sugar cataract and its prevention in rat lenses with aldose reductase inhibitors. Exp. Eye Res. 1988 ; 46: 37–47.
18. 18 Gorog P., Kovacs IB. The inhibitory effect of nonsteroidal anti‐inflammatory agents on aggregation of red blood cells in vitro. J. Pharm. Pharmacol. 1970 ; 22: 86–92.
19. 19 Dawkins PD, Gould BJ, Smith MJH. Inhibitory effect of salicylate on the incorporation of L‐[U‐ 14 C]leucine into protein of rat tissue preparations in vitro. Biochem. J. 1966 ; 99: 703–7.
20. 20 Bayer B., Kruth HS, Vaughan M., Beaven MA. Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J. Pharmacol. Exp. Ther. 1979 ; 210: 106–11.
21. 21 de Mello MCF, Bayer BM, Beaven MA. Evidence that prostaglandins do not have a role in the cytostatic action of anti‐inflammatory drugs. Biochem. Pharmacol. 1979 ; 29: 311–18.
22. 22 Mizushima Y., Sakai S., Yamaura M. Mode of stabilising action of non‐steroidal anti‐inflammatory drugs on erythrocyte membrane. Biochem. Pharmacol. 1969 ; 19: 227–34.
23. 23 Schwartz CS, Mandel HG. The selective inhibition of microbial RNA synthesis by salicylate. Biochem. Pharmacol. 1971 ; 21: 771–85.
24. 24 Northover BJ. Indomethacin‐A calcium antagonist. Gen. Pharmacol. 1977 ; 8: 293–6.
25. 25 Kantor HS, Hampton M. Indomethacin in submicromolar concentrations inhibits cyclic AMP‐dependent protein kinase. Nature 1978 ; 276: 841–2.